Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Hodgson

Data Editor, Pharma

Cambridge, U.K
John is Data Editor, Pharma within Informa’s Pharma Intelligence division. He honed skills as a writer, analyst and consultant, commentating on science and business in biotechnology over three decades. He prefers evidence to received wisdom, and believes that new is interesting but improved is better.
Advertisement
Set Alert for Articles By John Hodgson

Latest From John Hodgson

Stock Scan Q1 2018: A Slump And A Proper Correction

The story of the first quarter of 2018 is the impact of the general stock downturn at the end of January and the selective recovery that followed. But even though AbbVie and others had their own private yo-yos, the real correction took a while.

Sales & Earnings Companies

STORM CEO Outlines Business Model And Pipeline Goals

Keith Blundy, CEO of STORM Therapeutics, discusses the companys founding and upcoming milestones.  

Business Strategies Commercial

Novo Seeds: Investing In Biopharma Growth

Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how this financing arm aligns with Novo’s broader strategy.

StartUps and SMEs Commercial

IOnctura CEO On Pipeline Strategy And Funding Goals

IOnctura’s CEO Catherine Pickering outlines the company’s business model and its approach to cancer R&D targeting the tumor microenvironment.

StartUps and SMEs Companies

Stock Scan March 2018: Trading Down, Pairing Up

Merger and acquisition, or collaboration at least, was in the air during March as big pharma took stock of its opportunities in the midst of a disturbed market.

Commercial M & A

Indisputable: Humira, Biologics Dominate Pharma Sales In 2017

Demand for the top-selling drug, Humira, continues to break all sales records, leading a charge in which, for the first time, a majority of the top 30 selling drugs were biologics. But 2017 also saw one multiple blockbuster drug lose over 75% of it's sales for reasons other than loss of exclusivity or market withdrawal. 

Biologics Commercial
See All
Advertisement
UsernamePublicRestriction

Register